Evaluating an Interactive Cancer Communication System (ICCS) in Lung Cancer

Brief Summary

Official Title: “Interactive Cancer Communication System (ICCS) in Lung Cancer: Evaluating Survival Benefits. Center of Excellence in Cancer Communication Research: Using Technology to Enhance Cancer Communication and Improve Clinical Outcomes”

This study will examine the potential for an Interactive Cancer Communication System (ICCS) to impact not only psychosocial outcomes such as quality of life but also length of survival in an advanced stage lung cancer population. Two hypotheses will be tested: the Comprehensive Health Enhancement Support System- Lung Cancer (CHESS- LC) will significantly improve patient quality of life and length of overall survival as compared to a usual care control group.

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
  • Study Primary Completion Date: April 2014

Detailed Clinical Trial Description

The prognosis for Non-Small Cell Lung Cancer patients remains poor despite recent advances in anti-cancer therapies. A lung cancer diagnosis often inflicts fear, despair, and hopelessness on patients and loved ones. For lung cancer patients in particular, a population where palliation rather than cure is often the focus, interventions addressing communication about various types of suffering are crucial to quality of life (QOL). Our Center has done extensive research testing CHESS (Comprehensive Health Enhancement Support System), a non-commercial, web-based information and support system. The recent Clinician Integration Project tested the impact of CHESS versus an Internet only Control group on QOL for caregivers of advanced stage lung cancer patients. This study yielded an unanticipated finding that CHESS may have a survival benefit for patients as one year survival was significantly increased in the CHESS group (50%) compared to Internet (34.2%). As this project did not focus on patient outcomes, follow-up with a well-formulated study designed and powered to address specific hypotheses of the nature of this effect is critical. The proposed study will specifically test QOL and survival effects of CHESS on lung cancer patients. Using sites in Wisconsin, Connecticut,Houston, and Chicago, we will randomly assign 376 advanced lung cancer patients to two study arms: a patient control group receiving Usual Care (including access to a computer and Internet) and a group given access to the CHESS website. Patients may invite a caregiver to participate. Patients will be followed for 18 months or until patient death.

Interventions Used in this Clinical Trial

  • Other: CHESS website for lung cancer patient + internet access if needed
    • The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use. It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills. Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services. An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: CHESS with Clinician Report + Internet access
    • An Internet-based system, Comprehensive Health Enhancement Support System for Lung Cancer(CHESS-LC) integrates over 14 services to provide tailored cancer information, support, and interactive tools.
  • Active Comparator: Usual care with Internet access
    • Control group patients will be given a list of URLs for 10-high quality lung cancer-related sites

Outcome Measures for this Clinical Trial

Primary Measures

  • Compared to a Usual Care control, CHESS will significantly improve lung cancer patient Quality of Life.
    • Time Frame: 12-month intervention
      Safety Issue?: No
  • Compared to a Usual Care control, CHESS will significantly improve patient influence length of survival of lung cancer patient.
    • Time Frame: 12-month intervention
      Safety Issue?: No

Secondary Measures

  • Examine the effects of CHESS use on self-determination theory (SDT) constructs.
    • Time Frame: 12 mos.
      Safety Issue?: No
  • Examine the factors that moderate effect of CHESS use on self-determination theory (SDT) constructs.
    • Time Frame: 12 mos.
      Safety Issue?: No
  • Examine whether these constructs mediate the effects of CHESS use on patient quality of life.
    • Time Frame: 12 mos.
      Safety Issue?: No
  • Examine whether treatment participation mediates the effect patient quality of life has on survival.
    • Time Frame: 12 mos/
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria

  • All patients must be diagnosed with non-small cell lung cancer (Stage IIIA non surgical, IIIB or IV)
  • All patients must be within 12 months of their primary lung cancer diagnosis or metastatic or recurrence disease.
  • All patients must be at least 18 years of age,
  • All patients must have an ECOG Performance Status rating of level 0, 1 or 2.
  • If patients have brain metastases, they must be stable
  • All patients must be under the care of a clinician who has consented to participate in the study.
  • All patients must be able to speak and read English (educational attainment of at least 6th grade).
  • All patients will be invited to have a caregiver also participate in the study, however this is not required.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial: No

Clinical Trial Investigator Information

  • Lead Sponsor
    • University of Wisconsin, Madison
  • Collaborator
    • Harry Gray Cancer Center Hartford Hospial
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • James Cleary, M.D., Principal Investigator, University of Wisconsin, Madison
    • Lori DuBenske, Ph.D., Principal Investigator, University of Wisconsin, Madison

Source

Clinical Trials content is provided directly by the US National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01012401